# Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas

> **NCT02333565** · PHASE2 · COMPLETED · sponsor: **Assistance Publique Hopitaux De Marseille** · enrollment: 20 (actual)

## Conditions studied

- Recurrent Meningiomas
- Resistant Meningiomas

## Interventions

- **DRUG:** Everolimus
- **DRUG:** Octreotide

## Key facts

- **NCT ID:** NCT02333565
- **Lead sponsor:** Assistance Publique Hopitaux De Marseille
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-22
- **Primary completion:** 2019-01-21
- **Final completion:** 2023-05-24
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2023-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02333565

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02333565, "Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02333565. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*